Skip to content
207.878.2770mail@immucell.com
Immucell
Immediate Immunity™
Immucell
  • About ImmuCell
    • About ImmuCell
    • Our Purpose
    • Management and Directors
    • Career Opportunities
    • Contact Us
  • First Defense
    • Product Line Overview
    • Manufacturing Facility Expansion
    • Manufacturing Facility Virtual Tour
    • Testimonials
  • Re-Tain
    • Re-Tain® for Mastitis
    • CMT for Mastitis
  • Sales & Distributors
    • Sales Team
    • Distributors
  • News
  • Investors
  • About ImmuCell
    • About ImmuCell
    • Our Purpose
    • Management and Directors
    • Career Opportunities
    • Contact Us
  • First Defense
    • Product Line Overview
    • Manufacturing Facility Expansion
    • Manufacturing Facility Virtual Tour
    • Testimonials
  • Re-Tain
    • Re-Tain® for Mastitis
    • CMT for Mastitis
  • Sales & Distributors
    • Sales Team
    • Distributors
  • News
  • Investors

STOCK QUOTE

PRESS RELEASES

Recent News | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014
SEC FILINGS
SEC FIlings

XBRL Documents

Annual Report and Proxy
CORPORATE GOVERNANCE
ICCC Code of Conduct

Charter and Powers of the Audit Committee

Nominating Committee Charter

Management & Directors

2018 Press Releases

12-11-18 ImmuCell Announces USDA Approval of Dual-Force™ First Defense®

11-13-18 ImmuCell Announces Financial Results for Third Quarter of 2018

11-08-18 ImmuCell to Participate at 9th Annual Craig-Hallum Alpha Select Conference

11-07-18 ImmuCell to Announce Financial Results for Third Quarter of 2018

09-25-18 ImmuCell Announces Issuance of Human Food Safety Technical Section Complete Letter for its Purified Nisin Product

08-13-18 ImmuCell Announces Financial Results for Second Quarter of 2018

08-07-18 ImmuCell to Announce Financial Results for Second Quarter of 2018

08-07-18 ImmuCell Hires Senior Director of Quality

07-25-18 ImmuCell Announces Sale of Certain Non-Core Assets

07-10-18 ImmuCell Announces Preliminary Sales Results for Second Quarter of 2018

06-25-18 ImmuCell to Join Russell Microcap Index

05-14-18 ImmuCell Announces Financial Results for First Quarter of 2018

05-07-18 ImmuCell to Announce Financial Results for First Quarter of 2018

02-08-18 ImmuCell Announces Preliminary Financial Results for Fourth Quarter and Full Year 2017

02-06-18 ImmuCell to Announce Financial Results for Fourth Quarter and Full Year 2017

01-30-18 ImmuCell Appoints Two New Members to its Board of Directors

COMPANY CONTACT

Michael F. Brigham
President & CEO
mail@immucell.com
207.878.2770

INVESTOR CONTACT
Lytham Partners, LLC
iccc@lythampartners.com
602.889.9700

Contact Us

56 Evergreen Drive
Portland, ME 04103

Office: 207.878.2770

Sales: 1.800.IMMUCELL

mail@immucell.com

NASDAQ: ICCC

Privacy Policy
Terms of Use

Recent News

10-07-25 ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 of 2025

09-29-25 ImmuCell Announces Selection of its Next President and CEO

08-14-25 ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2025

Follow Us

Find us on:

Facebook page opens in new windowYouTube page opens in new window
Copyright © 2020 ImmuCell Corporation
  • Home
  • About ImmuCell
  • First Defense
  • Re-Tain
  • Sales Team
  • Distributors
  • News
  • Investors
  • Contact Us
Footer Menu
Go to Top
Skip to content
Open toolbar Accessibility Tools

Accessibility Tools

  • Increase TextIncrease Text
  • Decrease TextDecrease Text
  • GrayscaleGrayscale
  • High ContrastHigh Contrast
  • Negative ContrastNegative Contrast
  • Light BackgroundLight Background
  • Links UnderlineLinks Underline
  • Readable FontReadable Font
  • Reset Reset